Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Murine interleukin-11 (mIL-11) is a cytokine belonging to the gp130 family. It exerts pleiotropic actions on various cell types, including hematopoietic, hepatic, stromal, epithelial, neural, and osteoclast cells. The mechanism of action involves the formation of a high-affinity receptor complex with the interleukin-11 receptor (IL-11R) and the transmembrane signaling receptor gp130, which subsequently induces gp130-dependent signaling. Structural and functional studies have identified three distinct receptor binding sites on mIL-11, analogous to those found in interleukin-6, supporting the model of a hexameric receptor complex. Murine IL-11 has been shown to stimulate proliferation in murine plasmacytoma cells, primitive bone marrow progenitor cells, megakaryocyte precursors, and hippocampus neuronal progenitor cells. Its expression is widespread in normal murine tissues, with notable levels in the hippocampus and developmentally regulated expression in the testis, suggesting roles in neural and testicular function, including accelerating spermatogenesis recovery after cytotoxic therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on murine interleukin-11.